Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
"What else do you have to do that will actually have to affect the Iranians' calculus?" said Amos Hochstein, who served as U.S. special envoy for international energy affairs...World Politicsread more
Reports of tensions may have been sparked by Kraft Heinz's underperformance and because of accounting problems at the packaged goods company.Investingread more
SpaceX used its high speed boat called "Ms. Tree" to catch the nosecone its Falcon 9 rocket after Monday's launch.Investing in Spaceread more
FedEx sued the U.S. government, saying it should not be held liable if it inadvertently shipped products that violated a Trump administration ban on exports to some Chinese...Traderead more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
The leaders of Japan and China got off to a tense start but have made significant progress in turning around their relations in recent years.Asia Politicsread more
Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
Citi Private Bank says it has maintained an "overweight" stance on stocks in China, Hong Kong, Taiwan and South Korea.Asia Marketsread more
Stocks in Asia slipped on Tuesday, while investors looked toward a meeting between U.S. President Donald Trump and Chinese President Xi Jinping set to happen later in the...Asia Marketsread more
A week of dovish fireworks out of the central banking community has just gone by with most of the world's leading central banks now guiding towards easing in light of downside...Commentaryread more
Five Below Inc.: "We almost pulled the trigger and told the ActionAlertsPlus.com club that it was the right level to buy. I mean, this thing's all the way down to $103. It is incredibly oversold. I like it here, just like I like some of the techs. I like that one."
Splunk Inc.: "This is another one. This is a data center play. I can't tell you when it's going to bottom. I can tell you that it's doing well, and that's the problem in a bear market. The doing well does not translate to [a] stock going higher."
Crown Castle Intl.: "The best one [in the 5G space] is Qualcomm. It's got the same yield as Crown Castle. You do have a lot of volatility involving Apple. 5G, I think, is two years away. I've been trying to recommend Broadcom and Qualcomm, but I just can't tell you to do it yet 'cause it's too far. "
Square Inc.: "Here's the problem with Square. This is, again, the thing that just drives me crazy. It is really good. It is doing well. But it's up 78 percent. Twilio's up 200 percent. As soon as you see these gains, people just can't stop selling. "
3D Systems Corp.: "Didn't like the quarter. Don't buy. Not the one to be in."
Dana Inc.: "That thing is down big. It's down 50 percent. I would actually like to own one of these tech stocks that's not doing badly that people think are doing badly because we're in a bear market in tech. "
Alibaba Group Holding Ltd.: "If you're Vice President [Mike] Pence, you want to make it so that they're not the biggest e-commerce play on the planet. You want to take them down. And that's why I will recommend no Chinese stocks, because when you have a vice president [who] wants to take down the stock market in China, why should I recommend a Chinese stock? "
Coherus Biosciences Inc.: "The biosimilar market is too crowded. I'd rather be on the other side of the trade and be in the ones who make the original drugs."
Snap Inc.: "Still too early to buy Snapchat."